These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 26703975

  • 1. A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.
    Crum MF, Trevaskis NL, Williams HD, Pouton CW, Porter CJ.
    Pharm Res; 2016 Apr; 33(4):970-82. PubMed ID: 26703975
    [Abstract] [Full Text] [Related]

  • 2. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA, Chalmers DK, Pouton CW, Porter CJH.
    Mol Pharm; 2018 Jun 04; 15(6):2355-2371. PubMed ID: 29659287
    [Abstract] [Full Text] [Related]

  • 3. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.
    Crum MF, Trevaskis NL, Pouton CW, Porter CJ.
    Mol Pharm; 2017 Feb 06; 14(2):394-405. PubMed ID: 28002666
    [Abstract] [Full Text] [Related]

  • 4. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Pouton CW, Porter CJ, LFCS Consortium.
    Pharm Res; 2013 Dec 06; 30(12):3059-76. PubMed ID: 23661145
    [Abstract] [Full Text] [Related]

  • 5. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R, Williams HD, Warren DB, Mohsin K, Porter CJ, Pouton CW.
    Eur J Pharm Sci; 2013 Jul 16; 49(4):748-60. PubMed ID: 23684915
    [Abstract] [Full Text] [Related]

  • 6. Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.
    Stillhart C, Imanidis G, Griffin BT, Kuentz M.
    Pharm Res; 2014 Dec 16; 31(12):3426-44. PubMed ID: 24962509
    [Abstract] [Full Text] [Related]

  • 7. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
    Suys EJA, Brundel DHS, Chalmers DK, Pouton CW, Porter CJH.
    J Control Release; 2021 Mar 10; 331():45-61. PubMed ID: 33450318
    [Abstract] [Full Text] [Related]

  • 8. Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.
    Devraj R, Williams HD, Warren DB, Porter CJ, Pouton CW.
    J Pharm Sci; 2014 Apr 10; 103(4):1050-63. PubMed ID: 24470073
    [Abstract] [Full Text] [Related]

  • 9. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Porter CJ, Pouton CW, Communicated on Behalf of the LFCS Consortium.
    J Pharm Sci; 2014 Aug 10; 103(8):2441-55. PubMed ID: 24985238
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate.
    Cho YD, Park YJ.
    Arch Pharm Res; 2014 Feb 10; 37(2):193-203. PubMed ID: 23754165
    [Abstract] [Full Text] [Related]

  • 11. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL, Trevaskis NL, Feeney OM, Edwards GA, Perlman ME, Ambler CM, Porter CJH.
    Mol Pharm; 2017 Dec 04; 14(12):4525-4538. PubMed ID: 29076741
    [Abstract] [Full Text] [Related]

  • 12. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.
    Keemink J, Mårtensson E, Bergström CAS.
    Mol Pharm; 2019 Mar 04; 16(3):921-930. PubMed ID: 30628771
    [Abstract] [Full Text] [Related]

  • 13. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
    O'Shea JP, Faisal W, Ruane-O'Hora T, Devine KJ, Kostewicz ES, O'Driscoll CM, Griffin BT.
    Eur J Pharm Biopharm; 2015 Oct 04; 96():207-16. PubMed ID: 26215636
    [Abstract] [Full Text] [Related]

  • 14. Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.
    Xu Y, Wang Y, Li XM, Huang Q, Chen W, Liu R, Chen B, Wei P.
    Drug Dev Ind Pharm; 2014 Jul 04; 40(7):972-9. PubMed ID: 23692349
    [Abstract] [Full Text] [Related]

  • 15. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N, Xia D, Holm R, Gan Y, Müllertz A, Yang M, Mu H.
    Eur J Pharm Sci; 2014 Jan 23; 51():204-10. PubMed ID: 24134899
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.
    Do TT, Van Speybroeck M, Mols R, Annaert P, Martens J, Van Humbeeck J, Vermant J, Augustijns P, Van den Mooter G.
    Int J Pharm; 2011 Jul 29; 414(1-2):118-24. PubMed ID: 21596119
    [Abstract] [Full Text] [Related]

  • 19. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
    Griffin BT, Kuentz M, Vertzoni M, Kostewicz ES, Fei Y, Faisal W, Stillhart C, O'Driscoll CM, Reppas C, Dressman JB.
    Eur J Pharm Biopharm; 2014 Apr 29; 86(3):427-37. PubMed ID: 24184675
    [Abstract] [Full Text] [Related]

  • 20. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM, Williams HD, Pouton CW, Porter CJ.
    J Control Release; 2014 Oct 28; 192():219-27. PubMed ID: 25058571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.